AstraZeneca has reported a robust rise in revenue in 2025, driven by strong demand for its cancer medicines, and struck an ...

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence for durvalumab, ...

Pascal Soriot suggests UK-US agreement will not be enough to revive plan to expand Cambridge site ...

AstraZeneca stock rose 230p (1.64 per cent) to 14,118 per share within an hour of the London stockmarket opening this morning ...

AstraZeneca's full-year 2025 results are due on 10 February. Learn what investors should watch including Tagrisso sales, ...

Profit after tax rose to $10.2 billion in 2025 from $7.0 billion a year earlier, AstraZeneca said in a statement. Revenue increased nine percent to $58.7 billion, boosted by a rise in cancer drug ...

A planned investment deal between the Government and AstraZeneca is not going ahead because it did not “add up for the UK taxpayer”, science minister Sir Chris Bryant said. He told MPs the Government ...

Anglo-Swedish drugmaker AstraZeneca has announced a positive recommendation from the National Institute for Health and Care Excellence (NICE) for Imfinzi (durvalumab), a perioperative treatment ...

AstraZeneca’s cancer medicine sales rose 14% in 2025, with upcoming disease expansions a foundation for further growth in ...

China is AstraZeneca's second-largest market after the United States - Copyright AFP/File Jonathan NACKSTRAND China is AstraZeneca's second-largest market after the ...

AstraZeneca started trading on the NYSE (New York Stock Exchange) this week after delisting from NASDAQ ADS after the end of ...

Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Note: Hover over the donut graph to view ...